Abstract
Amyloid precursor protein (APP), ADAM 10, and beta-site-APP cleaving enzyme (BACE) alterations were evaluated in platelets of 31 patients with Alzheimer disease (AD) and 15 age-matched controls. A significant modification of these proteins and enzymes involved in the amyloid cascade was detected from the earliest clinically detectable disease stage. This observation suggests that AD is associated with an early metabolic derangement toward amyloidogenic pathways and supports the potential value of APP and secretase measurements for early diagnosis of AD.
MeSH terms
-
ADAM Proteins
-
ADAM10 Protein
-
Aged
-
Alzheimer Disease / blood*
-
Alzheimer Disease / diagnosis
-
Amyloid Precursor Protein Secretases
-
Amyloid beta-Protein Precursor / blood*
-
Aspartic Acid Endopeptidases / blood*
-
Biomarkers
-
Blood Platelets / chemistry*
-
Endopeptidases
-
Female
-
Humans
-
Male
-
Membrane Proteins / blood*
-
Metalloendopeptidases / blood*
-
Neuropsychological Tests
Substances
-
Amyloid beta-Protein Precursor
-
Biomarkers
-
Membrane Proteins
-
Amyloid Precursor Protein Secretases
-
Endopeptidases
-
Aspartic Acid Endopeptidases
-
BACE2 protein, human
-
BACE1 protein, human
-
ADAM Proteins
-
Metalloendopeptidases
-
ADAM10 Protein
-
ADAM10 protein, human